MILED Trial Informational Video 

Powering LAM Research Webinar 

 


The MILED Trial is a new research study designed to answer the question of whether we should be starting sirolimus at low doses earlier in the course of LAM, before symptoms develop and while lung function is still normal, similar to the manner in which we treat diabetes and high blood pressure early to prevent future heart and kidney complications.

You may be eligible if you:

  • Are an adult woman with LAM
  • Have an FEV1 greater than 70% predicted
  • Are not currently taking sirolimus

During the study, participants will:

  • Attend 8 study visits over 2 years (about one visit every 4 months)
  • Complete blood tests, a physical exam, and pulmonary function tests at visits
  • Answer questions about breathing, fatigue and quality of life
  • Take one capsule every day (1 mg sirolimus or a sugar pill) throughout the study
  • Record their pill taking and any side effects in an electronic diary

Participants will receive:

  • Physical exams, pulmonary function tests, a chest x-ray, and laboratory tests free of charge
  • Study drug (either 1 mg sirolimus or placebo) throughout the study
  • Reimbursement for travel expenses to attend each study visit


You can enroll in the MILED Trial and still participate in the LAM protocol at the NIH.

To get more information or to see if you may be eligible, please contact Susan McMahan Sellers, BSN, RN, or Carrie L. Keininger, BSN, RN. We can answer your questions, provide additional information, and refer you to the closest MILED study site.  

Susan’s contact information is susan.mcmahan@uc.edu  | 513-558-4376 

Carrie's contact information is keinincl@ucmail.uc.edu | 513-558-5602

Sites that are welcoming new participants are located in Atlanta, Chicago, Cincinnati, Seattle, and New York City.


Please see the LAM Foundation’s website or clinicaltrials.gov for more details about the MILED Trial.

Please view the updated MILED Trial Travel Policy linked here.